Summit Therapeutics SMMT Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's other income (expense)?
- Summit Therapeutics (SMMT) reported other income (expense) of $5.79M in Q1 2026.
- How has Summit Therapeutics's other income (expense) changed year-over-year?
- Summit Therapeutics's other income (expense) increased by 47.0% year-over-year, from $3.94M to $5.79M.
- What is the long-term trend for Summit Therapeutics's other income (expense)?
- Over 3 years (2021 to 2025), Summit Therapeutics's other income (expense) has grown at a 83.1% compound annual growth rate (CAGR), from -$2.42M to $14.84M.
- What does other income (expense) mean?
- The net result of income and expenses not related to core business operations.
- How do you interpret other income (expense)?
- Positive values indicate supplemental income sources, while negative values reflect costs like currency fluctuations or non-core losses.
- How does other income (expense) compare across companies?
- Varies significantly based on cash holdings and international exposure; peers may show different levels of interest income.